A replicate designed bioequivalence study to compare two fixed-dose combination products of artesunate and amodiaquine in healthy Chinese volunteers

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6009-6015

  Liu, Yun ^a   Hu, Chaoying ^a   Liu, Gangyi ^a   Jia, Jingying ^a   Yu, Chen ^a   Zhu, Jianmin ^a   Zheng, Qingsi ^b   Zhang, Kanyin E ^c  

^a Clinical Research Center Shanghai Xuhu Central Hospital   (China)

^b Guilin Pharmaceutical Co Ltd   (China)

^c Vivo Development Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMODIAQUINE PLUS ARTESUNATE; ASPARTATE AMINOTRANSFERASE; DIHYDROARTEMISININ; AMODIAQUINE; AMODIAQUINE, ARTESUNATE DRUG COMBINATION; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIOVENTRICULAR BLOCK; BIOEQUIVALENCE; BLINDNESS; BLOATING; BLOOD SAMPLING; CHINESE; CLINICAL ARTICLE; COUGHING; DIARRHEA; DIET RESTRICTION; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; ELIMINATION RATE CONSTANT; FATIGUE; HEART PALPITATION; HUMAN; INFLUENZA; LEUKOCYTE COUNT; LOSS OF APPETITE; MALE; MOUTH ULCER; NAUSEA; NIGHT SWEAT; NORMAL HUMAN; NOSE OBSTRUCTION; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OTITIS; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; SORE THROAT; STOMACH DISEASE; SYSTEMIC CIRCULATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CONTROLLED STUDY; DRUG COMBINATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; THERAPEUTIC EQUIVALENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG COMBINATIONS; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84907916711     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02617-14     Document Type: Article

References (14)

1. World Health Organization. 2010. Guidelines for treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2010. World malaria report. World Health Organization, Geneva, Switzerland.
3. German PI, Aweeka FT. 2008. Clinical pharmacology of artemisinin-based combination therapies. Clin. Pharmacokinet. 47:91-102. http://dx.doi.org/10.2165/00003088-200847020-00002.
4. Sanofi-Aventis. 2010. Summary of product characteristics: ASAQ Winthrop (artesunate, amodiaquine). Sanofi-Aventis, Reston, VA.
5. Navaratnam V, Ramanathan S, Wahab MS, Siew Hua G, Mansor SM, Kiechel JR, Vaillant M, Taylor WR, Olliaro P. 2009. Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur. J. Clin. Pharmacol. 65:809-821. http://dx.doi.org/10.1007/s00228-009-0656-1.
6. Fortin A, Verbeeck RK, Jansen FH. 2011. Comparative oral bioavailability of non-fixed and fixed combinations of artesunate and amodiaquine in healthy Indian male volunteers. Eur. J. Clin. Pharmacol. 67:267-275. http: //dx.doi.org/10.1007/s00228-010 0911-5.
7. European Medicines Agency (EMA)/Committee for Medicinal Products for Human Use (CHMP). 2010. Guideline on the investigation of bioequivalence. EMA/CHMP, London, United Kingdom.
8. European Medicines Agency (EMA)/Committee for Medicinal Products for Human Use (CHMP). 2011. Guideline on bioanalytical method validation. EMA/CHMP, London, United Kingdom.
9. World Health Organization. 2006. Guidelines on registration requirements to establish interchangeability and for in vivo bioequivalence studies, annex 7 and 9, WHO Technical Report Series 937, 4th report. World Health Organization, Geneva, Switzerland.
10. Chinese FDA. 2005. Guideline for human bioavailability and bioequivalence studies for pharmaceuticals. China Food and Drug Administration, Beijing, China.
11. WHO. 2000. Good laboratory practice, special programme for research and training in tropical diseases. World Health Organization, Geneva, Switzerland.
12. Hanpithakpong W, Kamanikom B, Dondorp AM, Singhasivanon P, White NJ, Day NP, Lindegardh N. 2008. A liquid chromatographictandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 876:61-68. http://dx.doi.org/10.1016/j .jchromb.2008.10.018.
13. Hodel EM, Zanolari B, Mercier T, Biollaz J, Keiser J, Olliaro P, Genton B, Decosterd LA. 2009. A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877:867-886. http://dx.doi.org/10.1016/j.jchromb.2009.02.006.
14. U.S. FDA. 2001. Statistical approaches to establishing bioequivalence, guidance to industry. Center for Drug Evaluation and Research (CDER). U.S. FDA, Rockville, MD.